- Home
- HSCS vs DYAI Comparison
HSCS vs DYAI Comparison
Compare HSCS & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | DYAI |
|---|---|---|
| Founded | 2007 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 17.0M |
| IPO Year | 2022 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HSCS | DYAI |
|---|---|---|
| Price | $3.31 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 124.8K | 123.0K |
| Earning Date | 09-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,319.00 | ★ $3,090,345.00 |
| Revenue This Year | $295.93 | $113.16 |
| Revenue Next Year | $18,321.05 | $94.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.63 | $0.34 |
| 52 Week High | $5.25 | $1.60 |
Technical Indicators
Market Signals| Indicator | HSCS | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 30.36 |
| Support Level | $1.84 | $0.34 |
| Resistance Level | $3.72 | $0.87 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 6.32 | 13.60 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.